Peter Salzmann Insider Profile

11 Followers
Peter Salzmann, CEO, Director at Immunovant, holds 994.79K shares in Immunovant (Ticker: IMVT), holds 2.78K shares in Corbus Pharmaceuticals (Ticker: CRBP). Most recently, Peter Salzmann Sold ― shares of Immunovant on Oct 18, 2024 for an estimated value of 261.85K.
tipranks
Peter Salzmann

Peter Salzmann
Immunovant (IMVT)
CEO, Director

Ranked #97,423 out of 99,335 Corporate Insiders

Profitable Transactions

22%
6 out of 27 Profitable Transactions

Average Return

-126.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$31M
99.83%
0.17%
A breakdown of Peter Salzmann's holdings

Insider Roles

Immunovant
(IMVT)
CEO, Director
Corbus Pharmaceuticals
(CRBP)
Director
Roles that Peter Salzmann holds in companies

Most Profitable Insider Trade

Stock:
Immunovant
(IMVT)
Rating:Informative Sell
Date:Jan 09, 2024 - Today
Return:+30.00%
The most profitable trade made by Peter Salzmann

Peter Salzmann's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Immunovant
Oct 18, 2024
CEO, Director
Informative Sell
261.85K
$30.98M
Corbus Pharmaceuticals
Jun 03, 2024
Director
Uninformative Buy
$51.74K
List of latest transactions for each holding click on a transaction to see Peter Salzmann's performance on stock

Peter Salzmann insider profile FAQ

What is the percentage of profitable transactions made by Peter Salzmann?
The percentage of profitable transactions made by Peter Salzmann is 22%.
    What is the average return per transaction made by Peter Salzmann?
    The average return per transaction made by Peter Salzmann is -126.30%.
      What stocks does Peter Salzmann hold?
      Peter Salzmann holds: IMVT, CRBP stocks.
        What was Peter Salzmann’s latest transaction?
        Peter Salzmann latest transaction was an Informative Sell of $261.85K.
          What was Peter Salzmann's most profitable transaction?
          Peter Salzmann’s most profitable transaction was an Informative Sell of IMVT stock on January 9, 2024. The return on the trade was 30.00%.
            What is Peter Salzmann's role in Immunovant?
            Peter Salzmann's role in Immunovant is CEO, Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.